Autonomix Medical: 5.2M Warrants In-The-Money
Ticker: AMIX · Form: 10-Q · Filed: Aug 13, 2024 · CIK: 1617867
Sentiment: neutral
Topics: warrants, dilution, financials, no-revenue
TL;DR
Autonomix Medical has 5.2M warrants in the money as of June 30, 2024. No revenue reported.
AI Summary
Autonomix Medical, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported no revenue for the quarter. As of June 30, 2024, Autonomix Medical had 5,257,929 warrants in-the-money, indicating a potential for significant dilution or exercise activity.
Why It Matters
The large number of in-the-money warrants suggests potential future share issuance, which could impact existing shareholders through dilution.
Risk Assessment
Risk Level: medium — The presence of a large number of in-the-money warrants indicates potential future dilution, which is a significant risk for current shareholders.
Key Numbers
- $0.00 — Revenue (No revenue reported for the quarter ending June 30, 2024.)
- 5,257,929 — In-the-money warrants (Indicates potential future dilution or exercise activity.)
Key Players & Entities
- Autonomix Medical, Inc. (company) — Filer of the 10-Q
- June 30, 2024 (date) — End of the reporting period
- 5,257,929 (dollar_amount) — Number of in-the-money warrants
FAQ
What was Autonomix Medical's revenue for the quarter ending June 30, 2024?
Autonomix Medical reported $0.00 in revenue for the quarter ending June 30, 2024.
How many warrants were in-the-money for Autonomix Medical as of June 30, 2024?
As of June 30, 2024, there were 5,257,929 outstanding and exercisable warrants in-the-money.
Were any stock options in-the-money for Autonomix Medical as of March 31, 2024?
No outstanding or exercisable stock options were in-the-money as of March 31, 2024.
What is the company's fiscal year end?
Autonomix Medical's fiscal year ends on March 31.
What is the company's business address?
The company's business address is 21 Waterway Avenue, Suite 300, The Woodlands, TX 77380.
Filing Stats: 4,611 words · 18 min read · ~15 pages · Grade level 16.1 · Accepted 2024-08-13 17:00:40
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value AMIX The Nasdaq Stock Mar
- $250,000 — xcess of the federally insured limit of $250,000. The Company has not experienced losses
- $0 — ne 30, 2024 and 2023 , the Company paid $0 and $ 0.1 million, respectively, of off
Filing Documents
- amix20240630_10q.htm (10-Q) — 732KB
- ex_652079.htm (EX-31.1) — 11KB
- ex_652080.htm (EX-31.2) — 11KB
- ex_652081.htm (EX-32.1) — 5KB
- ex_652082.htm (EX-32.2) — 5KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-24-026451.txt ( ) — 4676KB
- amix-20240630.xsd (EX-101.SCH) — 43KB
- amix-20240630_cal.xml (EX-101.CAL) — 18KB
- amix-20240630_def.xml (EX-101.DEF) — 336KB
- amix-20240630_lab.xml (EX-101.LAB) — 311KB
- amix-20240630_pre.xml (EX-101.PRE) — 355KB
- amix20240630_10q_htm.xml (XML) — 641KB
FINANCIAL INFORMATION
PART I FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements 4 Unaudited Condensed Balance Sheets as of June 30, 2024 and March 31, 2024 4 Unaudited Condensed Statement of Operations for the three months ended June 30, 2024 and 2023 5 Unaudited Condensed Statements of Stockholders ' Equity for the three months ended June 30, 2024 and 2023 6 Unaudited Condensed Statement of Cash Flows for the three months ended June 30, 2024 and 2023 7 Notes to the Unaudited Condensed Financial Statements 8 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 24 Item 4.
Controls and Procedures
Controls and Procedures 24
OTHER INFORMATION
PART II OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 26 Item 1A.
Risk Factors
Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosures 26 Item 5. Other Information 26 Item 6. Exhibits 27
Signatures
Signatures 28 3 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION Item 1.
Financial Statements
Financial Statements Autonomix Medical, Inc. Condensed Balance Sheets (Unaudited) (in thousands, except share and per share data) As of June 30, March 31, 2024 2024 Assets Current assets: Cash and cash equivalents $ 6,751 $ 8,608 Other current assets 325 783 Total current assets 7,076 9,391 Long term assets: Fixed assets, net 19 16 Total long term assets 19 16 Total Assets $ 7,095 $ 9,407 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 287 $ 492 Accrued expenses 476 285 Total current liabilities 763 777 Long term liabilities: Long term debt - convertible notes, net of unamortized debt discount 1,043 1,002 Total long term liabilities 1,043 1,002 Total Liabilities $ 1,806 $ 1,779 Commitments and contingencies (Note 5) Stockholders' equity: Preferred stock, $ 0.001 par value, 10,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively $ - $ - Common stock, $ 0.001 par value, 500,000,000 shares authorized as of June 30, 2024 and March 31, 2024, respectively, 19,242,081 and 18,846,094 shares issued and outstanding as of June 30, 2024 and March 31, 2024, respectively 19 19 Additional paid-in capital 46,938 46,578 Accumulated deficit ( 41,668 ) ( 38,969 ) Total Stockholders' Equity 5,289 7,628 Total Liabilities and Stockholders' Equity $ 7,095 $ 9,407 See accompanying notes to the unaudited condensed financial statements. 4 Table of Contents Autonomix Medical, Inc. Condensed Statements of Operations (Unaudited) Three Months Ended June 30, (in thousands, except share and per share data) 2024 2023 Operating expenses: General and administrative $ 1,799 $ 503 Research and development 954 368 Total operating expenses 2,753 871 Loss from operations ( 2,753 ) ( 871 ) Other (expense) income: Interest expense ( 41